[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551958":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":27,"overallOfficials":35,"centralContacts":39,"locations":49,"responsibleParty":66,"collaborators":13,"id":68,"slug":13,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":13,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":13,"studyType":80,"phases":81,"briefSummary":82,"conditions":83,"keywords":13,"overallStatus":52,"whyStopped":13,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Isfahan University of Medical Sciences","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Western Ontario and McMaster University Osteoarthritis index (WOMAC)","Filling out the WOMAC questionnaire, evaluating the measures related to knee function","1, 3, and 6 months. The second injection is repeated in day 90 after first injection.",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","SUPPORTIVE_CARE",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":23,"description":24,"interventionNames":25},"Treatment","EXPERIMENTAL","Patients with moderate to severe osteoarthritis, Kellgren-Lawrence grade 2,3 in both knees; accompanied by mild to moderate pain and swelling are included.",[26],"Biological: Exosome",[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"BIOLOGICAL","Exosome","intra-articular injection is suggested for two times: day 1and day 90",[22],[34],"EVs",[36],{"name":37,"affiliation":5,"role":38},"Leila Dehghani, Dr","PRINCIPAL_INVESTIGATOR",[40,45],{"name":37,"role":41,"phone":42,"phoneExt":43,"email":44},"CONTACT","36202020","031","l_dehghani2002@yahoo.com",{"name":46,"role":41,"phone":47,"phoneExt":43,"email":48},"Masoud Soleimani, Prof","03136202020","a70.leiladehghani@gmail.com",[50],{"facility":51,"status":52,"city":53,"state":13,"zip":13,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Leila Dehghani","RECRUITING","Isfahan","Iran","IR",{"type":57,"coordinates":58},"Point",[59,60],51.67462,32.65246,{"lat":60,"lon":59},[63,65],{"name":64,"role":41,"phone":42,"phoneExt":43,"email":44},"Leila Dehghani, Assisstant Prof",{"name":46,"role":41,"phone":42,"phoneExt":43,"email":48},{"type":38,"investigatorFullName":51,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"Dr","100551958",false,"NCT06466850","Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients","The Efficacy of Allogenic Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients","Inclusion Criteria:\n\n* Chronic history (for at least 3 months) of knee joint pain\n* Body mass index (BMI) between 21.5 and 29.5\n* Radiographically documented knee osteoarthritis of grades 1 to 3 (Kellgren-Lawrence (K-L) radiographic classification scale)\n\nExclusion Criteria:\n\n* Rheumatoid arthritis and other rheumatic diseases\n* Varus or valgus more than 10 degrees; lateral subluxation of the patella\n* Deformity at the joint levels or adjacent to the knee due to fracture or any other injury\n* Complete rupture of the ligament and meniscus leading to laxity or locking\n* Serious systemic, oncohematological, autoimmune diseases; history of severe allergy; serious failure of vital organs, inability to walk\n* Hyaluronic acid infiltration within the previous six months\n* Hemoglobin levels \\\u003C10 g\u002FdL;","ALL","45 Years","75 Years",{"count":78,"type":79},20,"ESTIMATED","INTERVENTIONAL",[15],"Present research focuses on the potential of exosomes, which are small vesicles secreted by mesenchymal stem cells (MSCs), as a therapeutic approach for osteoarthritis (OA).\n\nOA is a degenerative joint disorder characterized by the destruction of cartilage and loss of extracellular matrix. It's associated with pro-inflammatory cytokines and increased expression of matrix metalloproteinase (MMP) and \"a disintegrin and metalloproteinase with thrombospondin motifs\" (ADAMTS).\n\nMSCs have been explored as a new treatment for OA over the last decade1. It's suggested that the paracrine secretion of trophic factors, in which exosomes play a crucial role, contributes to the mechanism of MSC-based treatment of OA.\n\nExosomes derived from MSCs may suppress OA development. They carry bioactive molecules of the parental cells, including non-coding RNAs (ncRNAs) and proteins and anti-inflammatory factors. These exosomes have shown a significant impact on the modulation of various physiological behaviors of cells in the joint cavity.\n\nThis research provides hope for developing more effective and predictable methods of using MSC-derived exosomes for OA treatment.",[84],"Osteoarthritis, Knee","2025-09-08",{"date":87,"type":88},"2025-09-15","ACTUAL",{"date":90,"type":88},"2024-01-01",{"date":92,"type":79},"2026-12-25",{"name":5,"class":6},1]